IBJNews

Lilly consolidated into testosterone drug lawsuit

Back to TopCommentsE-mailPrintBookmark and Share

Abbott Laboratories, AbbVie Inc. must face lawsuits consolidated in federal court in Chicago that claim they hid the risks of using the testosterone-replacement drug AndroGel, a panel of judges ruled Friday.

The market for testosterone replacement drugs, which include AndroGel and Axiron, made by Indianapolis-based Eli Lilly and Co., is worth $1.6 billion annually. The consolidation will encompass all suits against makers of testosterone-replacement pills, including Lilly, the panel said in its order.

Lilly had $178.7 million in Axiron sales in 2013.    

Abbott and AbbVie, a company Abbott spun off last year, are both based in the Chicago area, and “a significant number” of AndroGel suits already are pending before U.S. District Judge Matthew Kennelly there, the panel said. Kennelly will oversee pretrial information exchanges as part of the case consolidation.

The decision to collect the AndroGel cases before Kennelly comes after the U.S. Food and Drug Administration said it will re-examine the safety of testosterone-replacement drugs after studies showed the medicine posed an increased risk of heart attack and stroke.

“Abbott separated its research-based pharmaceutical business into a new public biopharmaceutical company called AbbVie in January 2013,” Scott Stoffel, an Abbott spokesman, said in an e-mailed statement. “With the separation, the U.S. commercial rights and associated responsibilities for AndroGel passed to AbbVie.”

Dirk Van Eeden, a spokesman for North Chicago, Ill.-based AbbVie, said the company supported the consolidation “in the interest of consistency and efficiency.”

Low T

While only about 45 AndroGel cases have been filed in federal courts around the U.S. so far, Kennelly may wind up overseeing thousands once suits against other manufacturers are filed and consolidated with the ones against Abbott and AbbVie, the Panel on Multidistrict Litigation said.

Abbott and AbbVie have been accused in patient suits of starting an $80 million marketing campaign in 2012 to promote AndroGel for a condition known as Low T. Television ads encouraged men complaining of low energy and lack of sexual drive to take the testosterone-boosting medicine, according to the plaintiffs.

Other companies that sell testosterone-boosting medicines, such as Pfizer Inc. and Actavis Inc., opposed consolidating cases over their products with the AndroGel suits against Abbott and AbbVie, the panel said.

Common questions

The panel said the lawsuits involve common questions of fact, and centralizing them in Chicago will promote efficiency.

Putting all the cases before Kennelly will help speed the litigation, said Alex MacDonald, a Boston-based plaintiffs’ lawyer representing patients who took the medicines. MacDonald sued Abbott and AbbVie in federal court in Boston last month on behalf of a former AndroGel user who suffered a stroke while taking the testosterone supplement.

“Testosterone supplements are a lifestyle drug that treat a contrived condition by subjecting men to deadly risks of heart attacks and strokes,” MacDonald said in an e-mail Friday.

ADVERTISEMENT

  • Injustice for justice
    You are greatly mistaken Mr. McDonald many testosterone recipients don't just take it as a lifestyle choice. Some have real conditions like pituitary tumors that stop our bodies from producing it (Hypogonadism) or other muscle conditions that affect strength. You should be ashamed for that comment alone, but if this stuff is being prescribed under false pretenses go get them. Just don't leave out the reality of the need for many people so you can make your buck. 2 wrongs don't make a right. R.Braun
  • VA Wife
    My 59 year-old husband was under close medical supervision after filing an upgrade status to his service connected disability. His claim began in 2008 -he did so without realizing how this would eventually capture his serious heart health decline after medications to lower his high cholesterol led to a one time only low normal reading for testosterone - stains lower hormones in some individuals - he was placed on Low- T and just as the study group he experienced 3 possibly 4 heart attacks in a years time. His health decline is well documented by the VA - there is not family history of early heart disease - his mother lived to be 84 and also had the same high cholesterol. How much ore proof does a person need?Lab test taken during this period after Low T was prescribed shows a sharp increase in his blood cumulative clotting ability which substantiates his increased risk of developing a embolism leading to a stroke.

Post a comment to this story

COMMENTS POLICY
We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
 
You are legally responsible for what you post and your anonymity is not guaranteed.
 
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
 
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
 
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
 

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
ADVERTISEMENT